NCT05668572: A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine |
|
|
| Active, not recruiting | 3 | 12000 | RoW | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)（GARDASIL®） | Beijing Health Guard Biotechnology, Inc | Human Papillomavirus Infection | 07/22 | 02/23 | | |
NCT05662020: A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China |
|
|
| Active, not recruiting | 3 | 2750 | RoW | Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9 | Beijing Health Guard Biotechnology, Inc, Yunnan Center for Disease Control and Prevention, Mile City Center for Disease Control and Prevention, Qiubei County Center for Disease Control and Prevention, Yanshan County Center for Disease Control and Prevention, National Institutes for Food and Drug Control, China, Shanghai Stem Pharmaceutical Development Co., Ltd. | Human Papillomavirus Infection | 11/22 | 03/28 | | |
